Evaluation of TcpF-A2-CTB Chimera and evidence of additive protective efficacy of immunizing with TcpF and CTB in the suckling mouse model of Cholera

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Price, Gregory A ^a,b   Holmes, Randall K ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MIRIAM HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYTIC B POLYPEPTIDE VACCINE; CHOLERA VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; TOXIN COREGULATED PILUS F A2 CATALYTIC B POLYPEPTIDE VACCINE; TOXIN COREGULATED PILUS F CATALYTIC B POLYPEPTIDE VACCINE; TOXIN COREGULATED PILUS F VACCINE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL STRAIN; CHIMERA; CHOLERA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; SUCKLING; TREATMENT OUTCOME; VACCINATION; VACCINE PRODUCTION; VIBRIO CHOLERAE;

ANIMALS; ANIMALS, NEWBORN; ANIMALS, SUCKLING; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; BACTERIAL PROTEINS; CHOLERA; CHOLERA TOXIN; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; GENOTYPE; IMMUNIZATION; IMMUNOGLOBULIN A; INJECTIONS, INTRAPERITONEAL; MICE; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; VIBRIO CHOLERAE; WEIGHT LOSS;

VIBRIO CHOLERAE; VIBRIO CHOLERAE O1;

EID: 84864696038     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042434     Document Type: Article

References (50)

1. Sack DA, Sack RB, Nair GB, Siddique AK, (2004) Cholera. Lancet 363: 223-233.
2. WHO/UNICEF (2010) Status and progress towards the MDG target. In:Progress on sanitation and drinking water: 2010 update.: WHO Press. 6-13 p.
3. Sinclair D, Abba K, Zaman K, Qadri F, Graves PM, (2011) Oral vaccines for preventing cholera. Cochrane Database Syst Rev. pp. CD008603.
4. Plotkin SA, Orenstein WA, Offit PA, (2008) Vaccines. Philadelphia: Saunders/Elsevier. xvii, 1725 p.
5. Zhang RG, Scott DL, Westbrook ML, Nance S, Spangler BD, et al. (1995) The three-dimensional crystal structure of cholera toxin. J Mol Biol 251: 563-573.
6. Holmgren J, Lonnroth I, Svennerholm L, (1973) Fixation and inactivation of cholera toxin by GM1 ganglioside. Scand J Infect Dis 5: 77-78.
7. De Haan L, Hirst TR, (2004) Cholera toxin: a paradigm for multi-functional engagement of cellular mechanisms (Review). Mol Membr Biol 21: 77-92.
8. Kirn TJ, Taylor RK, (2005) TcpF is a soluble colonization factor and protective antigen secreted by El Tor and classical O1 and O139 Vibrio cholerae serogroups. Infect Immun 73: 4461-4470.
9. Manning PA, (1997) The tcp gene cluster of Vibrio cholerae. Gene 192: 63-70.
10. Craig L, Taylor RK, Pique ME, Adair BD, Arvai AS, et al. (2003) Type IV pilin structure and assembly: X-ray and EM analyses of Vibrio cholerae toxin-coregulated pilus and Pseudomonas aeruginosa PAK pilin. Mol Cell 11: 1139-1150.
11. Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, et al. (1988) Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168: 1487-1492.
12. Taylor RK, Miller VL, Furlong DB, Mekalanos JJ, (1987) Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci U S A 84: 2833-2837.
13. Kirn TJ, Lafferty MJ, Sandoe CM, Taylor RK, (2000) Delineation of pilin domains required for bacterial association into microcolonies and intestinal colonization by Vibrio cholerae. Mol Microbiol 35: 896-910.
14. Krebs SJ, Taylor RK, (2011) Protection and attachment of Vibrio cholerae mediated by the toxin-coregulated pilus in the infant mouse model. J Bacteriol 193: 5260-5270.
15. Kirn TJ, Bose N, Taylor RK, (2003) Secretion of a soluble colonization factor by the TCP type 4 pilus biogenesis pathway in Vibrio cholerae. Mol Microbiol 49: 81-92.
16. Megli CJ, Yuen AS, Kolappan S, Richardson MR, Dharmasena MN, et al. (2011) Crystal structure of the Vibrio cholerae colonization factor TcpF and identification of a functional immunogenic site. J Mol Biol 409: 146-158.
17. Hang L, John M, Asaduzzaman M, Bridges EA, Vanderspurt C, et al. (2003) Use of in vivo-induced antigen technology (IVIAT) to identify genes uniquely expressed during human infection with Vibrio cholerae. Proc Natl Acad Sci U S A 100: 8508-8513.
18. Holmgren J, Svennerholm AM, Lonnroth I, Fall-Persson M, Markman B, et al. (1977) Development of improved cholera vaccine based on subunit toxoid. Nature 269: 602-604.
19. Kundu J, Mazumder R, Srivastava R, Srivastava BS, (2009) Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge. FEMS Immunol Med Microbiol 56: 179-184.
20. Pierce NF, Cray WC Jr, Sacci JB Jr, (1982) Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms. Infect Immun 37: 687-694.
21. Srivastava R, Sinha VB, Srivastava BS, (1979) Re-evaluation of antibacterial and antitoxin immunities in experimental cholera. Indian J Med Res 70: 369-373.
22. Isaka M, Yasuda Y, Kozuka S, Miura Y, Taniguchi T, et al. (1998) Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit. Vaccine 16: 1620-1626.
23. Isaka M, Yasuda Y, Mizokami M, Kozuka S, Taniguchi T, et al. (2001) Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine 19: 1460-1466.
24. McKenzie SJ, Halsey JF, (1984) Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 133: 1818-1824.
25. Price GA, Russell MW, Cornelissen CN, (2005) Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice. Infect Immun 73: 3945-3953.
26. Wu HY, Russell MW, (1998) Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine 16: 286-292.
27. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A, (1997) Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 65: 2676-2684.
28. Curlin GT, R Levine, K. M. A Aziz, A. S. M Rahman, W. F Verwey, (1975) Field trial of cholera toxoid, p. 314-335. Proceedings of the Eleventh Joint Conference of the US-Japan Cooperative Medical Science Program: Department of Health, Education, and Welfare, Washington, D. pp. C.
29. Levine MM, Nalin DR, Craig JP, Hoover D, Bergquist EJ, et al. (1979) Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg 73: 3-9.
30. Noriki H, (1976) Evaluation of toxoid field trial in the Philippines, p. 302-310. In H Fukumi and Y Zimaka (ed), Proceedings of the 12th Joint Conference of the US-Japan Cooperative Medical Science Program: National Institute of Japan, Tokyo, Japan.
31. WHO (2010) Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 85: 117-128.
32. Hajishengallis G, Hollingshead SK, Koga T, Russell MW, (1995) Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 154: 4322-4332.
33. Jobling MG, Holmes RK, (1992) Fusion proteins containing the A2 domain of cholera toxin assemble with B polypeptides of cholera toxin to form immunoreactive and functional holotoxin-like chimeras. Infect Immun 60: 4915-4924.
34. Rask C, Fredriksson M, Lindblad M, Czerkinsky C, Holmgren J, (2000) Mucosal and systemic antibody responses after peroral or intranasal immunization: effects of conjugation to enterotoxin B subunits and/or of co-administration with free toxin as adjuvant. Apmis 108: 178-186.
35. Li X, Erbe JL, Lockatell CV, Johnson DE, Jobling MG, et al. (2004) Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infect Immun 72: 7306-7310.
36. Sultan F, Jin LL, Jobling MG, Holmes RK, Stanley SL Jr, (1998) Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin. Infect Immun 66: 462-468.
37. Ujiiye A, Nakatomi M, Utsunomiya A, Mitsui K, Sogame S, et al. (1968) Experimental Cholera in Mice I. First Report on the Oral Infection. Tropical Medicine 10: 65-71.
38. Goel AK, Jiang SC, (2010) Genetic determinants of virulence, antibiogram and altered biotype among the Vibrio cholerae O1 isolates from different cholera outbreaks in India. Infect Genet Evol 10: 815-819.
39. Schild S, Nelson EJ, Bishop AL, Camilli A, (2009) Characterization of Vibrio cholerae outer membrane vesicles as a candidate vaccine for cholera. Infect Immun 77: 472-484.
40. Schild S, Nelson EJ, Camilli A, (2008) Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun 76: 4554-4563.
41. Tamplin ML, Ahmed MK, Jalali R, Colwell RR, (1989) Variation in epitopes of the B subunit of El Tor and classical biotype Vibrio cholerae O1 cholera toxin. J Gen Microbiol 135: 1195-1200.
42. Marchlewicz BA, Finkelstein RA, (1983) Immunological differences among the cholera/coli family of enterotoxins. Diagn Microbiol Infect Dis 1: 129-138.
43. Fazil MH, Kumar S, Farmer R, Pandey HP, Singh DV, (2011) Binding efficiencies of carbohydrate ligands with different genotypes of cholera toxin B: molecular modeling, dynamics and docking simulation studies. J Mol Model.
44. Ansaruzzaman M, Bhuiyan NA, Nair BG, Sack DA, Lucas M, et al. (2004) Cholera in Mozambique, variant of Vibrio cholerae. Emerg Infect Dis 10: 2057-2059.
45. Nair GB, Faruque SM, Bhuiyan NA, Kamruzzaman M, Siddique AK, et al. (2002) New variants of Vibrio cholerae O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh. J Clin Microbiol 40: 3296-3299.
46. Nair GB, Qadri F, Holmgren J, Svennerholm AM, Safa A, et al. (2006) Cholera due to altered El Tor strains of Vibrio cholerae O1 in Bangladesh. J Clin Microbiol 44: 4211-4213.
47. Raychoudhuri A, Patra T, Ghosh K, Ramamurthy T, Nandy RK, et al. (2009) Classical ctxB in Vibrio cholerae O1, Kolkata, India. Emerg Infect Dis 15: 131-132.
48. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J, (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334: 349-355.
49. Dertzbaugh MT, Elson CO, (1993) Reduction in oral immunogenicity of cholera toxin B subunit by N-terminal peptide addition. Infect Immun 61: 384-390.
50. Reed LJ, Muench H, (1938) A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 27: 493-497.